Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Spine (Phila Pa 1976). 2011 Apr 15;36(8):E513–E518. doi: 10.1097/BRS.0b013e3181f52cb5

Figure 5.

Figure 5

Cre recombinase activity in tamoxifen-treated Col2a1-CreER mouse and acceleration of bone formation in the IVD of tamoxifen-treated Col2a1-CreER/β-cateninfl/fl mouse. Col2a1-CreER (A), Col2a1-CreER/Rosa26A (B), β-catenin fl/fl (C, E and G) or Col2a1-CreER/β-cateninfl/fl (D, F and H) mice received three daily injections of tamoxifen (200 µg/20 µl/day) when they were 5-days-old. The vertebrae were dissected at ages of 5-weeks-old (A and B) or 9-weeks-old (C–H). The tissues sections were subjected to β-galactosidase activity staining (A and B) or HE staining. Green bars represent EP and yellow arrows show bone formation. Bar, 300 µm.